Last reviewed · How we verify
Meningitis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Kanacin | KANAMYCIN | Bristol-Myers Squibb | Aminoglycoside Antibacterial | Gap junction beta-2 protein | 1973-01-01 | |
| Eryped | Erythromycin ethyl succinate | Arbor Pharms Llc | Macrolide | 1965-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Meningitis
- Arbor Pharms Llc · 1 drug in Meningitis
- Bristol-Myers Squibb · 1 drug in Meningitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Meningitis:
- Meningitis treatment updates — RSS
- Meningitis treatment updates — Atom
- Meningitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Meningitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/meningitis. Accessed 2026-06-10.
Related
- Meningitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing